What is the recommended protocol for administering Reglan (Metoclopramide) via Intravenous (IV) infusion?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Administration Protocol for IV Reglan (Metoclopramide)

For intravenous administration of Reglan (metoclopramide), administer 10 mg slowly over 1-2 minutes for most indications, with specific protocols required for chemotherapy-induced nausea and vomiting. 1

Standard IV Administration Protocol

  • For most indications (gastroparesis, facilitating small bowel intubation, radiological examinations), administer 10 mg doses slowly over a 1-2 minute period 1
  • Ensure proper patient identification and appropriate vascular access before administration 2
  • Have emergency medications (such as diphenhydramine) readily available to treat potential extrapyramidal reactions 1
  • Monitor vital signs before, during, and after administration 2

Specific Dosing Guidelines by Indication

Diabetic Gastroparesis

  • Administer 10 mg slowly IV over 1-2 minutes 1
  • May continue administration for up to 10 days before transitioning to oral therapy 1
  • For patients with renal impairment (creatinine clearance <40 mL/min), start with approximately half the recommended dose 1

Prevention of Chemotherapy-Induced Nausea and Vomiting

  • Administer as an infusion over at least 15 minutes, 30 minutes before chemotherapy 1
  • Initial dose: 1-2 mg/kg depending on emetogenic potential of chemotherapy regimen 1
  • For highly emetogenic drugs (cisplatin, dacarbazine), use 2 mg/kg per dose 1
  • For less emetogenic regimens, 1 mg/kg per dose may be adequate 1
  • Repeat every 2 hours for two doses, then every 3 hours for three doses 1
  • For doses exceeding 10 mg, dilute in 50 mL of parenteral solution 1

Prevention of Postoperative Nausea and Vomiting

  • Administer 10 mg IV near the end of surgery 1
  • May increase to 20 mg if needed 1

To Facilitate Small Bowel Intubation or Radiological Examinations

  • Adults and children >14 years: 10 mg IV over 1-2 minutes 1
  • Children 6-14 years: 2.5-5 mg IV 1
  • Children <6 years: 0.1 mg/kg IV 1

Dilution and Compatibility

  • For doses >10 mg, dilute in 50 mL of parenteral solution 1
  • Preferred diluent is Sodium Chloride Injection (normal saline) 1
  • When diluted in normal saline, can be stored frozen for up to 4 weeks 1
  • Avoid dilution with Dextrose-5% in Water if planning to freeze the solution 1
  • Metoclopramide is incompatible with several medications including diazepam, ketamine, lorazepam, nitroglycerin, phenytoin, and propofol during Y-site administration 3

Special Considerations

  • For patients with renal impairment (creatinine clearance <40 mL/min), start with approximately half the recommended dose 1
  • Metoclopramide undergoes minimal hepatic metabolism and can be used in patients with advanced liver disease who have normal renal function 1
  • Parenteral metoclopramide use should generally be limited to 1-2 days 4
  • Monitor closely for extrapyramidal symptoms, especially in younger patients and with higher doses 5

Management of Adverse Reactions

  • For acute dystonic reactions, administer 50 mg diphenhydramine intramuscularly 1
  • The most common adverse reactions include restlessness, drowsiness, fatigue, and lassitude 4
  • Extrapyramidal symptoms occur more frequently with high doses (≥2 mg/kg) or prolonged use 5
  • Children receiving doses ≥2 mg/kg have shown a 15% incidence of extrapyramidal reactions and 33% incidence of akathisia 5

Common Pitfalls to Avoid

  • Never administer IV metoclopramide rapidly as a bolus, as this increases the risk of adverse reactions 2, 1
  • Avoid prolonged use of parenteral metoclopramide (limit to 1-2 days when possible) 4
  • Be aware that children and young adults have an increased risk of extrapyramidal reactions 5
  • Ensure proper dilution for doses exceeding 10 mg 1
  • Verify compatibility when administering with other medications 3

References

Guideline

Proper Procedure for Administering a Test Dose of Intravenous Medication

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Metoclopramide: a dopamine receptor antagonist.

American family physician, 1990

Research

Metoclopramide: dose-related toxicity and preliminary antiemetic studies in children receiving cancer chemotherapy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1985

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.